Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and ...

Soft tissue sarcomas are rare solid tumors that are being increasingly classified and treated by subtype. Approximately 12,020 people will be diagnosed with a soft tissue sarcoma in the United States ...

Immutep (NASDAQ:IMMP) shares jumped sharply on Wednesday after the company announced that the U.S. Food and Drug ...

Sarcomas can invade surrounding tissue and can metastasize (spread) to other organs of the body, forming secondary tumors. The cells of secondary tumors are similar to those of the primary (original) ...

Ravin Ratan, MD, MEd, MD Anderson, delves into how treatment paradigms and considerations differ between adult patients and pediatric patients who have soft tissue sarcomas. Ravin Ratan, MD, MEd, ...

Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy. Blood-based markers such as NLR and ...

Immutep (IMM) stock soared 101% after FDA granted Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma. Market exclusivity & tax benefits await.

Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma Over three-fold increase in tumour ...

Developed by NCIS in partnership with institutes such as NCCS and international contributors, the handbook reflects Singapore ...

Canine soft tissue sarcomas (STS) constitute a heterogeneous group of mesenchymal tumours that present diverse morphological and clinical profiles. These neoplasms commonly affect the skin and ...